Phase 1 Bioavailability Study of SYR-322MET

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Healthy Volunteers

Interventions

DRUG

Alogliptin

Alogliptin 12.5 mg tablets

DRUG

Metformin Hydrochloride

Metformin hydrochloride 1000 mg tablets

DRUG

SYR-322MET

SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets